<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141905</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00069775</org_study_id>
    <nct_id>NCT03141905</nct_id>
  </id_info>
  <brief_title>Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease</brief_title>
  <official_title>Can a Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefits of renin angiotensin system (RAS) blockers and diuretics for blood pressure&#xD;
      control are well-established in chronic kidney diseases (CKD) patients; however, these agents&#xD;
      may become hazardous on &quot;sick-days&quot; that lead to volume depletion (dehydration), and increase&#xD;
      the risk of kidney function loss and acute kidney injury (AKI). It is not known how frequent&#xD;
      significant sick-days occur in CKD patients, or whether a patient self-managed Sick-Day&#xD;
      Protocol (SDP) that temporarily holds RAS blocker, diuretics, or other high risk medication&#xD;
      in an effort to preserve renal function, or prevent AKI. The purpose of the study is to asses&#xD;
      if a SDP, monitored remotely with a weekly automated phone survey , can improve outcomes in&#xD;
      CKD (such as slow renal function loss and AKI episodes) and reduce preventable service&#xD;
      utilization versus usual care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: implementing a self managed &quot;Sick-Day Protocol&quot; with telephone monitoring via&#xD;
      interactive voice survey dial-response system (IVSDRS) in CKD patients taking RAS blockers,&#xD;
      diuretics, metformin, or NSAIDs, will safely slow renal function loss, reduce the incidence&#xD;
      of acute kidney injury, and prevent urgent health utilization; in comparison to usual care.&#xD;
&#xD;
      Study Design: 6-month randomized trial of Sick-Day Protocol vs usual care&#xD;
&#xD;
      Randomization: In-block randomization stratified by use (with or without any other qualifying&#xD;
      medication) vs non-use of RAS blocker (with any other qualifying medication)&#xD;
&#xD;
      Intervention: Sick-Day Protocol (instructions for holding and resumption of certain medicines&#xD;
      in the event of dehydrating illness), IVRSDRS remote monitoring, augmented laboratory&#xD;
      monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC)&#xD;
&#xD;
      Study Population: Veterans across the VA Maryland Health Care System (VAMCHS) with a current&#xD;
      prescription for any type of RAS blocker, Diuretic, Metformin or NSAID.&#xD;
&#xD;
      Study Site: Baltimore VA Medical Center (BVAMC), VA Geriatrics Research Education and&#xD;
      Clinical Center (GRECC).&#xD;
&#xD;
      Specific Aims 1: Conduct a pragmatic trial comparing the renal function decline, incidence of&#xD;
      AKI, and urgent service utilization in eligible CKD patients provided with a self-managed&#xD;
      Sick-Day Protocol versus comparable patients receiving usual care.Specific Aim 2: Determine&#xD;
      the incidence of sick-days in the intervention arm using remote IVSDRS monitoring and&#xD;
      end-of-study survey of all participants. Specific Aim 3: Evaluate intervention arm&#xD;
      participants' usage of, and adherence to, the Sick-Day Protocol with remote IVSDRS&#xD;
      monitoring.&#xD;
&#xD;
      Study Measurements: laboratory-measured renal function, and patient- reported safety events&#xD;
      obtained per IVSDRS protocol. Emergency department (ED) visits, hospitalization, renal&#xD;
      progression, incidence of ESRD, and death will be measured in both groups along with patient&#xD;
      satisfaction.&#xD;
&#xD;
      Primary outcomes: 6-month change in renal function (eGFR), incidence of AKI episodes&#xD;
      (including ICD-10 code designated, and detectable creatinine-based changes in renal function&#xD;
      usingRIFLE criteria), preventable/urgent service utilization (to be ascertained using VA EHR&#xD;
      review)&#xD;
&#xD;
      Secondary outcomes: Determination of incidence of sick-day events (IVSDRS reporting, and&#xD;
      end-of-study self-report).&#xD;
&#xD;
      Tertiary:Adherence to self-management Sick-Day Protocol (based on IVSDRS reporting)&#xD;
&#xD;
      Analytic plans: Comparison between intervention and usual care participants of 6-month renal&#xD;
      function change, and frequency of AKI and hospitalization using generalized linear models and&#xD;
      Poisson regression methods, respectively. Similar regression methods will be used to&#xD;
      determine the adjusted frequency rate of sick-day incidents and participant response to&#xD;
      sick-days.&#xD;
&#xD;
      Public Health Relevance: Introduction of a self-management Sick-Day Protocol in conjunction&#xD;
      with coordinated care and IVSDRS surveillance can be an innovative strategy to improve renal&#xD;
      outcomes and reduce preventable service utilization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">October 7, 2020</completion_date>
  <primary_completion_date type="Actual">October 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Renal Function From Baseline to Study Completion;</measure>
    <time_frame>6 months (enrollment to study completion)</time_frame>
    <description>Laboratory measurement of creatinine at study entry and completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury Incidents</measure>
    <time_frame>6 months (enrollment to study completion)</time_frame>
    <description>Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ER Use and Hospitalization</measure>
    <time_frame>6 months (enrollment to study completion)</time_frame>
    <description>Participants with urgent service utilization including emergency department, hospitalization, and urgent care.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determination of Sick-day Incidents</measure>
    <time_frame>6 months from enrollment in study</time_frame>
    <description>Participants reporting sick-days via IVSDRS and end-of study visit survey ascertainment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence to the Self-management Sick-day Protocol</measure>
    <time_frame>6 months (enrollment to study completion)</time_frame>
    <description>Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>Safety Issues</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Sick-Day Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sick-Day Protocol</intervention_name>
    <description>Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
    <arm_group_label>Sick-Day Protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Standard clinical care</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Veterans with prescription for any type of RAS blocker, diuretic, Metformin or NSAID&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected death or dialysis within 6 months&#xD;
&#xD;
          -  No home or cellular telephone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://projectreporter.nih.gov/project_info_description.cfm?aid=9183807&amp;icde=33940674&amp;ddparam=&amp;ddvalue=&amp;ddsub=&amp;cr=4&amp;csb=default&amp;cs=ASC&amp;pball=</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <results_first_submitted>March 11, 2021</results_first_submitted>
  <results_first_submitted_qc>April 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Jeffrey Fink</investigator_full_name>
    <investigator_title>Division Head, General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>patient safety</keyword>
  <keyword>self-management</keyword>
  <keyword>remote monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03141905/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sick-Day Protocol</title>
          <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Usual Care: Standard clinical care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, but did not receive intervention. Withdrew prior to baseline visit.</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sick-Day Protocol</title>
          <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Usual Care: Standard clinical care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="315"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="313"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <population>Baseline creatinine/eGFR missing for 4 study participants, 3 in the usual care arm, and 1 in the intervention arm.</population>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="153"/>
                    <count group_id="B3" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.110" spread="13.128"/>
                    <measurement group_id="B2" value="43.783" spread="13.018"/>
                    <measurement group_id="B3" value="43.441" spread="13.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Renal Function From Baseline to Study Completion;</title>
        <description>Laboratory measurement of creatinine at study entry and completion</description>
        <time_frame>6 months (enrollment to study completion)</time_frame>
        <population>280 participants with complete laboratory data collection</population>
        <group_list>
          <group group_id="O1">
            <title>Sick-Day Protocol</title>
            <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care: Standard clinical care</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function From Baseline to Study Completion;</title>
          <description>Laboratory measurement of creatinine at study entry and completion</description>
          <population>280 participants with complete laboratory data collection</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.11" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-.010" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Kidney Injury Incidents</title>
        <description>Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria</description>
        <time_frame>6 months (enrollment to study completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sick-Day Protocol</title>
            <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care: Standard clinical care</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Kidney Injury Incidents</title>
          <description>Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AKI ICD-10 code on ED visit or admission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50% increase in Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ER Use and Hospitalization</title>
        <description>Participants with urgent service utilization including emergency department, hospitalization, and urgent care.</description>
        <time_frame>6 months (enrollment to study completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sick-Day Protocol</title>
            <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care: Standard clinical care</description>
          </group>
        </group_list>
        <measure>
          <title>ER Use and Hospitalization</title>
          <description>Participants with urgent service utilization including emergency department, hospitalization, and urgent care.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency Room</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgent Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Determination of Sick-day Incidents</title>
        <description>Participants reporting sick-days via IVSDRS and end-of study visit survey ascertainment.</description>
        <time_frame>6 months from enrollment in study</time_frame>
        <population>299 participants who completed all study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Sick-Day Protocol</title>
            <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care: Standard clinical care</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Sick-day Incidents</title>
          <description>Participants reporting sick-days via IVSDRS and end-of study visit survey ascertainment.</description>
          <population>299 participants who completed all study visits.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adherence to the Self-management Sick-day Protocol</title>
        <description>Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group)</description>
        <time_frame>6 months (enrollment to study completion)</time_frame>
        <population>Sick-Day Protocol group</population>
        <group_list>
          <group group_id="O1">
            <title>Sick-Day Protocol</title>
            <description>Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to the Self-management Sick-day Protocol</title>
          <description>Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group)</description>
          <population>Sick-Day Protocol group</population>
          <units>count of qualifying illnesses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Followed Sick-Day Protocol instructions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not stop medicines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stopped other medicines in addition to SDP qualifying.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sick-Day Protocol</title>
          <description>Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual Care: Standard clinical care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lab Alert: Hemoglobin ≤ 7.5 g/dL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lab Alert: Potassium ≥ 6.1 mEq/dL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Lab Alert: Glucose ≥ 499 mg/dL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Initiation of Hemodialysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lab Alert: Chloride ≥ 115 mEq/dL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lab Alert: Co2 ≤ 15 mEq/L</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the COVID-19 pandemic in-person visits were suspended on 3/12/2020 per institution and IRB mandate. Study lab measurements were delayed for 24 participants and not completed for 8 participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey C. Fink MD, MS (Principal Investigator)</name_or_title>
      <organization>University of Maryland, Baltimore</organization>
      <phone>410-328-4822</phone>
      <email>jfink@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

